Enabling SUD Digital Therapeutics Research to Improve Payor Adoption (R44- Clinical Trial Only)

The summary for the Enabling SUD Digital Therapeutics Research to Improve Payor Adoption (R44- Clinical Trial Only) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Enabling SUD Digital Therapeutics Research to Improve Payor Adoption (R44- Clinical Trial Only): To ensure that digital therapeutics that have been or are in the development for SUD are adopted, this funding opportunity concept aims to fund clinical trials that will generate convincing data to improve adoption by the payors.

Federal Grant Title:	Enabling SUD Digital Therapeutics Research to Improve Payor Adoption (R44- Clinical Trial Only)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Education Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-DA-23-018
Type of Funding:	Grant
CFDA Numbers:	93.279
CFDA Descriptions:	Information not provided
Current Application Deadline:	November 15th, 2022
Original Application Deadline:	November 15th, 2022
Posted Date:	June 29th, 2022
Creation Date:	June 29th, 2022
Archive Date:	December 21st, 2022
Total Program Funding:
Maximum Federal Grant Award:	$2,500,000
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No
Last Updated:	June 29th, 2022

Applicants Eligible for this Grant: Small businesses
Additional Information on Eligibility: Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-23-018.html
Grant Announcement Contact: NIH OER Webmaster
[email protected]
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
Similar Government Grants: • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...; • Education Activities for Responsible Analyses of Complex, Large-Scale Data (R25- Clinical ...; • Research on the Neuro-Immune Axis in the context of HIV and Substance Use (R01 Clinical Tr...; • Research on the Neuro-Immune Axis in the Context of HIV and Substance Use (R21 Clinical Tr...; • Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial option...; • NIDA Phase II Small Business Innovation Research (SBIR [R44]) Competing Renewal Awards; • Drug Abuse Aspects of Hiv/Aids and Other Infections; • Epidemiology of Drug Abuse
More Grants from the National Institutes of Health: • NINDS Research Education Opportunities (R25 Clinical Trial Not Allowed); • ML/AI Tools to Advance Genomic Translational Research (MAGen) - Development Sites (UG3/U...; • ML/AI Tools to Advance Genomic Translational Research (MAGen) - Coordinating Center (UG3/U...; • Mentored Career Development Award to Promote Faculty Diversity in Biomedical Research (K01...; • Mentored Career Development Award to Promote Faculty Diversity in Biomedical Research (K01...